原发性干燥综合征血清阴性患者唾液中抗 SSA/Ro52 和 -Ro60 干燥综合征阳性试验。

Seronegative patients with primary Sjögren's syndrome and non-pSS sicca test positive for anti-SSA/Ro52 and -Ro60 in saliva.

机构信息

Center of Oral/Head & Neck Oncology Research, UCLA School of Dentistry, Los Angeles, CA, USA; Department of Odontology, Section of Oral Biology and Immunopathology/Oral Medicine & Pathology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.

Center of Oral/Head & Neck Oncology Research, UCLA School of Dentistry, Los Angeles, CA, USA.

出版信息

Biochim Biophys Acta Mol Basis Dis. 2024 Jun;1870(5):167168. doi: 10.1016/j.bbadis.2024.167168. Epub 2024 Apr 17.

DOI:10.1016/j.bbadis.2024.167168

PMID:38641012

Abstract

OBJECTIVES

Testing for anti-SSA/Ro antibodies in serum is essential in the diagnostic work-up for primary Sjögren's syndrome (pSS). In this study, we aimed to validate our previous assay for detection of salivary anti-SSA/Ro52, and to develop assays for detection of salivary anti-SSA/Ro60 and for detection of anti-Ro52 and -Ro60 in plasma using the electric field-induced release and measurement (EFIRM) platform.

METHODS

Whole saliva samples from two independent Danish cohorts (DN1 and DN2) including 49 patients with pSS, 73 patients with sicca symptoms, but not fulfilling the classification criteria for pSS (non-pSS sicca), and 51 healthy controls (HC), as well as plasma samples from the DN1 cohort were analyzed using EFIRM to detect anti-SSA/Ro52 and -Ro60.

RESULTS

In the DN1 cohort, 100 % in the pSS group and 16 % in the non-pSS sicca group were serum anti-SSA/Ro positive by ELISA. EFIRM detected anti-SSA (Ro52 and/or -Ro60) in plasma and saliva in 100 % and 96 % patients with pSS, and 16 % and 29 % with non-pSS sicca. In the DN2 cohort, 80 % patients with pSS and 26 % with non-pSS sicca were serum anti-SSA/Ro positive. Salivary anti-SSA discriminated patients with pSS from HC and non-pSS sicca with an AUC range of 0.74-0.96 in the DN1 and DN2 cohorts. EFIRM discriminated pSS from non-pSS sicca with an AUC of 0.98 in plasma.

CONCLUSION

Our findings suggest that salivary anti-SSA/Ro antibodies are potential discriminatory biomarkers for pSS, which may also identify seronegative patients, addressing the unmet clinical need of early detection and stratification of pSS.

摘要

目的

检测血清中的抗 SSA/Ro 抗体对于原发性干燥综合征（pSS）的诊断至关重要。本研究旨在验证我们之前用于检测唾液抗 SSA/Ro52 的检测方法，并开发用于检测唾液抗 SSA/Ro60 和血浆中抗 Ro52 和 -Ro60 的检测方法，该方法使用电场诱导释放和测量（EFIRM）平台。

方法

使用 EFIRM 分析来自两个独立的丹麦队列（DN1 和 DN2）的全唾液样本，包括 49 例 pSS 患者、73 例干燥症状但不符合 pSS 分类标准的患者（非 pSS 干燥）和 51 名健康对照（HC），以及来自 DN1 队列的血浆样本，以检测抗 SSA/Ro52 和 -Ro60。

结果

在 DN1 队列中，pSS 组患者的血清抗 SSA/Ro 阳性率为 100%，而非 pSS 干燥组为 16%。EFIRM 在 100%的 pSS 患者和 96%的非 pSS 干燥患者的血浆和唾液中检测到抗 SSA（Ro52 和/或 -Ro60），而非 pSS 干燥患者的阳性率为 16%和 29%。在 DN2 队列中，80%的 pSS 患者和 26%的非 pSS 干燥患者的血清抗 SSA/Ro 阳性。唾液抗 SSA 在 DN1 和 DN2 队列中分别将 pSS 患者与 HC 和非 pSS 干燥患者区分开来，AUC 范围为 0.74-0.96。EFIRM 在血浆中区分 pSS 和非 pSS 干燥的 AUC 为 0.98。